X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Olinvacimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
Olinvacimab, an anti-VEGFR2 (Vascular Endothelial Growth Factor Receptors-2) molecule, is the company's lead asset. The molecule is currently undergoing multiple global clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Olinvacimab
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The data from the study suggested the possibility of using Olinvacimab for rGBM patients who no longer respond to Avastin in treating severe brain edema.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Olinvacimab,Immunotherapy
Therapeutic Area: Oncology Product Name: TTAC-0001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: PharmAbcine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 26, 2020
Details:
Binex is responsible for large-scale manufacturing of clinical investigational material for PharmAbcine for its global Phase 2 trials on olinvacimab + immunotherapy combination for metastatic triple negative breast cancer and trials on various common solid tumors.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
